PCO371 + Placebo
Phase 1Terminated 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hypoparathyroidism
Conditions
Hypoparathyroidism
Trial Timeline
Jul 23, 2020 → May 25, 2021
NCT ID
NCT04209179About PCO371 + Placebo
PCO371 + Placebo is a phase 1 stage product being developed by Chugai Pharmaceutical for Hypoparathyroidism. The current trial status is terminated. This product is registered under clinical trial identifier NCT04209179. Target conditions include Hypoparathyroidism.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04209179 | Phase 1 | Terminated |
| NCT02475616 | Phase 1 | Terminated |
Competing Products
9 competing products in Hypoparathyroidism
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| MBX 2109 | MBX Biosciences | Phase 2 | 47 |
| 400 µg of MBX 2109 once-weekly by subcutaneous injection + 200-1600 µg of MBX 2109 once-weekly by subcutaneous injection | MBX Biosciences | Phase 2 | 47 |
| recombinant human somatotropin | Eli Lilly | Pre-clinical | 23 |
| Palopegteriparatide | Ascendis Pharma | Pre-clinical | 20 |
| Palopegteriparatide (TransCon PTH) | Ascendis Pharma | Pre-clinical | 20 |
| Palopegteriparatide | Ascendis Pharma | Pre-clinical | 20 |
| EnteraBio's Oral Parathyroid Hormone (1-34) | Entera Bio | Phase 2 | 44 |
| EBP05 + Forteo 0.02 mg + EBP11 + EBP22 + EBP11-F2 + EBP11-F4 + EBP11-F1 + EBP11-F5 | Entera Bio | Phase 1 | 25 |
| EB612 (EBP05) + NATPARA/NATPAR | Entera Bio | Phase 2 | 44 |